Burfiralimab is a monoclonal IgG4 antibody targeting vimentin expressed on the surface of virus-infected cells, exhibiting broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation; it can be used in research on severe COVID-19.